Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Chemical aftertreatment – e.g. – acylation – methylation – etc.
Reexamination Certificate
2007-08-21
2007-08-21
Tsang, Cecilia J. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Chemical aftertreatment, e.g., acylation, methylation, etc.
C530S300000, C514S002600
Reexamination Certificate
active
11648773
ABSTRACT:
Methods for preparing viral neuraminidase inhibitors including antiviral peptides by specifically chemically modifying disulfide bonds in precursor molecules. A method of inhibiting viral neuraminidases by administering a viral neuraminidase inhibitor comprising an antiviral peptide prepared by the above methods and inhibiting the viral neuraminidase. Therapeutics for inhibiting viral neuraminidases, including effective amounts of viral neuraminidase inhibitors including antiviral peptides derived from selectively chemically modified disulfide bonds in precursor molecules, and present in a pharmaceutically acceptable carriers.
REFERENCES:
patent: 3888877 (1975-06-01), Sanders
patent: 4126676 (1978-11-01), Sanders
patent: 4162303 (1979-07-01), Sanders
patent: 4341762 (1982-07-01), Haast
patent: 4741902 (1988-05-01), Haast
patent: 5182260 (1993-01-01), Maraganore et al.
patent: 5676974 (1997-10-01), Valdes et al.
patent: 5723477 (1998-03-01), McDonald et al.
patent: 5955303 (1999-09-01), Au-Young et al.
patent: 5989857 (1999-11-01), Mundschenk
patent: 5994515 (1999-11-01), Hoxie
patent: 6613745 (2003-09-01), Gopalakrishnakone et al.
patent: 6670148 (2003-12-01), Mundschenk et al.
patent: 2002/0150975 (2002-10-01), Methfessel et al.
patent: 2003/0211465 (2003-11-01), Mundschenk et al.
patent: 2004/0192594 (2004-09-01), Reid et al.
patent: 2005/0031608 (2005-02-01), Reid et al.
patent: 2005/0255097 (2005-11-01), Reid et al.
patent: WO/2001/070173 (2001-09-01), None
Sanders, Murray, et al., New York Academy of Sciences, vol. 58, Art. 1, pp. 1-12 (1953), “Neurotoxoid Interference with Two Human Strains of Poliomyelitis in Rhesus Monkeys.”
Miller, Kent D. et al., “Inhibition of Virus-Induced Plaque Formation by Atoxic Derivatives of Purified Cobra Neurotoxins,”Biochimica et Biophysica Acta.,496, 192-196 (1977).
The Bureau of Biologics, The National Institute of Neurological and Communicative Disorders and Stroke, and Johns Hopkins University: Workshop on Modified Neurotoxin Treatment of Amyotrophic Lateral Sclerosis (1979).
Yourist, J.E. et al., “Inhibition of Herpes Simplex Virus Replication by Cobra α-Neurotoxoid,”J. gen. Virol.64:1475-1481 (1983).
Walkinshaw, Malcolm D. et al., “Three-dimensional structure of the “long” neurotoxin from cobra venom,”Proc. Natl. Acad. Sci. USA,vol. 77, No. 5, 2400-2404 (1980).
DuPont-Oxone Monopersulfate Compound.
“Reductive Cleavage of Disulfide Bridges in Ribonuclease,”Science,125:691 (1957).
Crestfield, Arthur M. et al., “The Preparation and Enzymatic Hydrolysis of Reduced and S-Carboxymethylated Proteins,”The Journal of Biological Chemistry,vol. 238:2, 622-627 (1963).
Ruegg Urs Th. et al., “Reductive Cleavage of Cystine Disulfides with Tributylphosphine,”Methods in Enzymol.
Burmeister, Elise et al., “A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry,”Anal. Biochem.,273, 73-80 (1999).
Mori, Isamu et al., “Selective targeting of habenular, thalamic midline and monoaminergic brainstem neurons by neurotropic influenza A virus in mice,”Journal of Neuroverology,5:355-362 (1999).
Matsuda, Kazyua, et al., In vitro demonstration of neural transmission of avian influenza A virus,J. of General Vir.86:1131-1139 (2005).
“Amino Acid Sequence Similarity Between Rabies Virus Glycoprotein and Snake Venom Cuaremimetic Neurotoxins,”Science,vol. 226:847-848 (1984).
Lentz, Thomas L., “Structure-Function Relationships of Curaremimetic Neurotoxin Loop 2 and of a Structurally Similar Segment of Rabies Virus Glycoprotein in Their Interaction with the Nicotinic Acetylcholine Receptor,”Biochem.30, 10949-10957 (1991).
Neri, P. et al., “Sequence homology between HIV gp120, rabies virus glycoprotein, and snake venom neurotoxins Is the nicotinic acetylcholine receptor an HIV receptor?”Arch Virol.,114:265-269 (1990).
Bracci, Luisa, et al., “Molecular Mimicry Between the Rabies Virus Glycoprotein and Human Immunodeficiency Virus-1 GP120: Cross-Reacting Antibodies Induced by Rabies Vaccination,”Blood,vol. 90:9, 3623-3628 (1997).
Johansson, Bert E. et al., “Variation in the Divalent Cation requirements of Influenza A Virus N2 Neuraminidases,”J. Biochem.134:345-352 (2003).
Austin Billy S.
Miller Kent D.
Kohn Kenneth I.
Kohn & Associates PLLC
Kosar Andrew D.
Tsang Cecilia J.
LandOfFree
Pan-antiviral peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pan-antiviral peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pan-antiviral peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861320